Clinical case of nebulized surfactant therapy for severe COVID-19-associated pneumonia at the 2nd stage of rehabilitation treatment

The development of an effective and safe drug for the treatment of patients with COVID-19 is currently an urgent task for the global medical community. Given that lung damage remains the predominant syndrome in COVID-19, and the development of acute respiratory distress syndrome (ARDS) is the most common reason for transfer to intensive care unit and connection to artificial lung ventilation, it seems promising to study the effectiveness and safety of surfactant therapy, successfully proven in practice in the treatment of adult and preterm infants ARDS. Despite the fact that most studies are devoted to the use of this method in patients in the acute stage, we present a case from our own practice of Surfactant-BL inhalation in a patient with COVID-19-associated pneumonia at the 2nd stage of rehabilitation treatment. Clinical signs of respiratory failure (RR 22 per minute, Sa O2 86% on atmospheric air, 95% on insufflation of humidified oxygen 7 L/min), high percentage of lung tissue damage according to thoracic CT (55% – CT3) on admission to the Medical Rehabilitation Unit, as well as a score of 6 on the NEWS2 scale served as a basis for the patient to receive Surfactant-BL inhalation for the indication «prevention of the development of acute respiratory distress syndrome» in a dosage of 75 mg twice a day for 5 days. Positive dynamics of clinical data at the end of the course of inhalations (decrease of RR to 16 per minute, increase of Sa O2 to 90% on atmospheric air and to 95% on insufflation of humidified oxygen 5 l/min, improvement of auscultatory picture), as well as the control thoracic CT scan, which showed a decrease of lung parenchyma damage to 45.2% (CT-2), indicated the effectiveness and safety of this method in the complex rehabilitation of COVID-19 patient, being a basis for further investigation of this issue

1. Calabrese F., Pezzuto F., Fortarezza F., Hofman P., Kern I., Panizo A. et al. Pulmonary pathology and COVID- 19: lessons from autopsy. The experience of European Pulmonary Pathologists. Virchows Arch. 2020;477(3):359–372. https://doi.org/10.1007/s00428-020-02886-6.

2. Polak S.B., Van Gool I.C., Cohen D., von der Thüsen J.H., van Paassen J. A systematic review of pathological findings in COVID- 19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. 2020;33(11):2128–2138. https://doi.org/10.1038/s41379-020-0603-3.

3. Li H., Liu S.M., Yu X.H., Tang S.L., Tang C.K. Coronavirus disease 2019 (COVID- 19): current status and future perspectives. Int J Antimicrob Agents. 2020;55(5):105951. https://doi.org/10.1016/j.ijantimicag.2020.105951.

4. Seyed Hosseini E., Riahi Kashani N., Nikzad H., Azadbakht J., Hassani Bafrani H., Haddad Kashani H. The novel coronavirus Disease-2019 (COVID- 19): Mechanism of action, detection and recent therapeutic strategies. Virology. 2020;551:1–9. https://doi.org/10.1016/j.virol.2020.08.011.

5. Odilov A.A., Tsimbalist N.S., Volkov A.V., Babichenko I.I. Organ changes found by postmortem examination in COVID- 19 patients. Arkhiv Patologii. 2020;82(6):63–69. (In Russ.) https://doi.org/10.17116/patol20208206163.

6. McDonald L.T. Healing after COVID- 19: are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2021;320(2):L257–L265. https://doi.org/10.1152/ajplung.00238.2020.

7. Rozenberg O.A. Pulmonary Surfactants for Acute and Chronic Lung Diseases (Part II). Obshchaya reanimatologiya = General Reanimatology. 2014;10(5): 69–86. (In Russ.) https://doi.org/10.15360/1813-9779-2014-5-69-86.

8. Rosenberg O.A. Pulmonary Surfactant Preparations and Surfactant Therapy for ARDS in Surgical Intensive Care (a Literature Review). Kreativnaya khirurgiya i onkologiya = Creative Surgery and Oncology. 2019;9(1):50–65. (In Russ.) https://doi.org/10.24060/2076-3093-2019-9-1-50-65.

9. Rosenberg O.A. Lung Surfactant and Its Use in Lung Diseases. Obshchaya reanimatologiya = General Reanimatology. 2007;3(1):66–77. (In Russ.) https://doi.org/10.15360/1813-9779-2007-1-66-77.

10. Takano H. Pulmonary surfactant itself must be a strong defender against SARS- CoV-2. Med Hypotheses. 2020;144:110020. https://doi.org/10.1016/j.mehy.2020.110020.

11. Crouch E., Wright J.R. Surfactant proteins a and d and pulmonary host defense. Annu Rev Physiol. 2001;63:521–554. https://doi.org/10.1146/annurev.physiol.63.1.521.

12. Crouch E., Hartshorn K., Ofek I. Collectins and pulmonary innate immunity. Immunol Rev. 2000;173:52–65. https://doi.org/10.1034/j.1600-065x.2000.917311.x.

13. Hartshorn K.L., White M.R., Voelker D.R., Coburn J., Zaner K., Crouch E.C. Mechanism of binding of surfactant protein D to influenza A viruses: importance of binding to haemagglutinin to antiviral activity. Biochem J. 2000;351 Pt. 2(Pt. 2):449–458. Available at: https://pubmed.ncbi.nlm.nih.gov/11023831.

14. Hillaire M.L., Haagsman H.P., Osterhaus A.D., Rimmelzwaan G.F., van Eijk M. Pulmonary surfactant protein D in first-line innate defence against influenza A virus infections. J Innate Immun. 2013;5(3):197–208. https://doi.org/10.1159/000346374.

15. Hartshorn K.L., Sastry K.N., Chang D., White M.R., Crouch E.C. Enhanced anti-influenza activity of a surfactant protein D and serum conglutinin fusion protein. Am J Physiol Lung Cell Mol Physiol. 2000;278(1):L90–8. https://doi.org/10.1152/ajplung.2000.278.1.L90.

16. Wright J.R. Immunomodulatory functions of surfactant. Physiol Rev. 1997;77(4):931–962. https://doi.org/10.1152/physrev.1997.77.4.931.

17. Numata M., Kandasamy P., Nagashima Y., Posey J., Hartshorn K., Woodland D., Voelker D.R. Phosphatidylglycerol suppresses influenza A virus infection. Am J Respir Cell Mol Biol. 2012;46(4):479–487. https://doi.org/10.1165/rcmb.2011-0194OC.

18. Fukushi M., Tohru M., Miyoshi-Akiyama T., Kubo S., Yamamoto K., Kudo K. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 virus. PLoS ONE. 2012;7(8):e42419. https://doi.org/10.1371/journal.pone.0042419.

19. Averyanov A.V., Klypa T.V., Balionis O.I., Bychinin M.V., Cherniak A.V., Troitskiy A.V., Trifonova E.V. Inhaled surfactant in patients with COVID- 19 who took high-flow oxygen: the results of a retrospective analysis. Meditsinskiy sovet = Medical Council. 2020;(17):75–80. (In Russ.) https://doi.org/10.21518/2079-701X-2020-17-75-80.

20. Bautin A.E., Avdeev S.N., Seyliev A.A., Shvechkova M.V., Merzhoeva Z.M., Trushenko N.V. et al. Inhalation surfactant therapy in the integrated treatment of severe COVID- 19 pneumonia. Tuberkulez i bolezni legkikh = Tuberculosis and Lung Diseases. 2020;98(9):6–12. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-9-6-12.